Dose Ranging Study of SPL7013 Gel for Treatment of Bacterial Vaginosis (BV)
Launched by STARPHARMA PTY LTD · Sep 12, 2010
Trial Information
Current as of May 29, 2025
Completed
Keywords
ClinConnect Summary
No description provided
Gender
FEMALE
Eligibility criteria
- Inclusion Criteria:
- • Women aged 18-45 years with a diagnosis of BV according to Amsel's criteria and a Nugent score of ≥4
- • Otherwise healthy
- Exclusion Criteria:
- • No active STIs
About Starpharma Pty Ltd
Starpharma Pty Ltd is an innovative Australian biotechnology company focused on the development and commercialization of proprietary dendrimer-based products for various therapeutic and diagnostic applications. With a strong commitment to advancing healthcare, Starpharma leverages its advanced drug delivery technologies to enhance the efficacy and safety of existing therapies, particularly in oncology and infectious diseases. The company is dedicated to addressing unmet medical needs through rigorous clinical trials and collaborations with leading research institutions and pharmaceutical partners, positioning itself at the forefront of biopharmaceutical innovation.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Las Vegas, Nevada, United States
Phoenix, Arizona, United States
Denver, Colorado, United States
Irving, Texas, United States
Virginia Beach, Virginia, United States
Patients applied
Trial Officials
Anne Macek, MD
Principal Investigator
contracted to Starpharma Pty Ltd
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported
Similar Trials